Business Wire01.04.17
Kyomed and Neogia are partnering to leverage common worldwide ambitions in e-health. Kyomed, a French start-up providing services in personalized medicine, and Neogia, an expert in connected healthcare wearables, part of Fabulasys, are attending CES 2017 to demonstrate how their collaboration contributes to the emergence of the next generation of connected, reliable and affordable devices for a more personalized approach of medicine. The partnership also helps to conduct successful clinical evaluation and get medical device marketing approvals for the latest wearables for healthcare.
This collaboration between an e-health technology company and a medical, clinical and regulatory expert engages clinical and technological co-developments. Kyomed brings its expertise in clinical validation, medical device regulation and user experience evaluation. Neogia shares its know-how in algorithmics and the conception of advanced technologies for health applications; the start-up also allows connections with U.S. institutions specialized in sleep health. The two companies' partership aims to accelerate the deployment of connected health devices for which clinical benefits and reliability have been demonstrated. This helps to engage patients, practitioners, healthcare institutions and insurances to adopt and recommend such devices to improve patients’ follow-up as patients’ day-to-day life.
During CES 2017 (Jan. 5-8), the companies will present their ambitions for Motio HW, a connected bracelet dedicated to patients suffering from sleep apnea. Motio HW is the first democratized medical device wearable that prevents, diagnoses and monitors the sleep apnea. It collects biometrics data (actimetry, heart rate, oxymetry, respiratory rate) which are sent to an application. Those data are processed by a unique algorithm to better understand the sleeping profile of each patient and improve the quality of life.
Neogia details the next steps of R&D for Motio HW, with a focus on miniaturization and the adaptation to other healthcare major issues like seniors falling. Kyomed plans clinical evaluations based on the four physiological parameters generated by the device.
This collaboration between an e-health technology company and a medical, clinical and regulatory expert engages clinical and technological co-developments. Kyomed brings its expertise in clinical validation, medical device regulation and user experience evaluation. Neogia shares its know-how in algorithmics and the conception of advanced technologies for health applications; the start-up also allows connections with U.S. institutions specialized in sleep health. The two companies' partership aims to accelerate the deployment of connected health devices for which clinical benefits and reliability have been demonstrated. This helps to engage patients, practitioners, healthcare institutions and insurances to adopt and recommend such devices to improve patients’ follow-up as patients’ day-to-day life.
During CES 2017 (Jan. 5-8), the companies will present their ambitions for Motio HW, a connected bracelet dedicated to patients suffering from sleep apnea. Motio HW is the first democratized medical device wearable that prevents, diagnoses and monitors the sleep apnea. It collects biometrics data (actimetry, heart rate, oxymetry, respiratory rate) which are sent to an application. Those data are processed by a unique algorithm to better understand the sleeping profile of each patient and improve the quality of life.
Neogia details the next steps of R&D for Motio HW, with a focus on miniaturization and the adaptation to other healthcare major issues like seniors falling. Kyomed plans clinical evaluations based on the four physiological parameters generated by the device.